Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04781127 · ClinicalTrials.gov registry record · Phase 1
Home-administered tDCS for Treatment of Depression
A Phase 1 study of Treatment-Resistant Depression and Unipolar Depression, sponsored by Soterix Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04781127 is a Phase 1 study of Treatment-Resistant Depression and Unipolar Depression that has completed, run by Soterix Medical. The registered enrollment target is 50 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04781127, a Phase 1 study of Treatment-Resistant Depression and Unipolar Depression, has completed, sponsored by Soterix Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT. 32 tDCS sessions of 30 minutes each will be delivered over 10 weeks.
Conditions Studied
Interventions
- DEVICE Soterix Medical mini-CT tDCS stimulator
Study Locations (1)
New York
- New York University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04781127
The ClinicalTrials.gov registry entry for NCT04781127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The listed sponsor is Soterix Medical, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Soterix Medical mini-CT tDCS stimulator is the first listed.
NCT04781127 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04781127 about?
NCT04781127 is a clinical study titled "Home-administered tDCS for Treatment of Depression". This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT. 32 tDCS sessions of 30 minutes each will be delivered over 10 weeks.
What is the current status of trial NCT04781127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-02-10. Estimated completion is 2022-08-10.
What conditions does trial NCT04781127 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression, Unipolar Depression.
What interventions are being tested in trial NCT04781127?
The interventions under investigation include: Soterix Medical mini-CT tDCS stimulator (DEVICE).
Who is sponsoring clinical trial NCT04781127?
This trial is sponsored by Soterix Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04781127 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DBS for Depression
RECRUITING · Phase 1
-
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
COMPLETED · Phase 1
-
Multiple Ascending Dose Phase 1 Study of ALA-3000
COMPLETED · Phase 1
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.